Device Trial Radar · NCT01033357
Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
Last checked: Nov 19, 2026Latest source record: Feb 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
222
Actual
Start
Mar 2008
Primary completion
Mar 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Angiotech PharmaceuticalsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 16, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the long term use of the experimental Vascular Wrap(TM) Paclitaxel-Eluting Mesh is safe in the treatment of subjects needing hemodialysis access (via an expanded polytetrafluoroethylene (ePTFE) graft).
Conditions
- End Stage Renal Failure on Dialysis
- Hyperplasia
Interventions
Graft, Vascular WrapDevice
Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
Lifespan® ePTFE Vascular Graft OnlyDevice
Vascular Graft only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nature and incidence of Adverse Events between treatment groups clinical difference in product-related adverse eventsTime frame: 4 years
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Ladenheim, Inc.
Fresno, California
Centinela Hospital
Inglewood, California
National Institute of Clinical Research
Los Angeles, California
27 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.